Skip Navigation

See how we are providing support for your patients during CORONAVIRUS (COVID‑19)

LEARN MORE

For U.S. Healthcare Professionals

See how we are providing support for your patients during CORONAVIRUS (COVID‑19)

LEARN MORE

For U.S. Healthcare Professionals

Patient.

Made for Selectivity
Made for Remission
Made for Now

  • Entyvio works through a gut-selective MOA by specifically binding to the α4β7 integrin and blocking its interaction with MAdCAM-1, which is mainly expressed on gut endothelial cells.1-7
  • Remission was evaluated at Week 52.1 Individual results may vary.
Healthcare professional.

For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.

More UC and CD patients start on Entyvio than any other biologic8*

*Based on an analysis of data in SHA database comparing quarterly UC and CD combined patient counts from January 2019 to May 2021 with “new start” defined as “bio-naïve” plus “switch” patients. “Bio-naïve” is defined as any patient with UC or CD who had no UC or CD biologic drug claims for the past 3 years. “Switch” is defined as any patient who previously used a different UC or CD biologic drug and switched to the current therapy in the past 3 years.

Only Entyvio (vedolizumab) Combines

Gut Selectivity2-7

Entyvio helps address inflammation where it occurs—the gut.1

Entyvio specifically binds to the α4β7 integrin and blocks the interaction between the α4β7 integrin and MAdCAM-1, which is mainly expressed on the GI tract endothelial cells.

Discover the MOA

Healthcare professional.

and

Long-Term Remission1,9,10

UC and CD patients achieved remission at Week 52 vs placebo in study populations that included bio‑naïve and anti‑TNFα‑
experienced patients.1,9,10

Individual results may vary.

Week 6 and Week 52:

View UC Data

View CD Data

Healthcare professional.

and

Safety DataFor the Long Term1,11-13

Clinical trials evaluated safety in more than 3300 adults (UC, CD, and healthy volunteers).1 A separate open-label study of up to 7 years demonstrated consistent results across safety parameters.11-13†

†In a single-arm, open-label extension study of 2243 patients who received Entyvio with a median exposure of 1072 days (range 1 to 3412 days).11-13

View Safety Profile

Healthcare professional.
Varsity Trial

ONLY ENTYVIO OFFERS RESULTS FROM THE first head-to-
head study of biologics in moderate to severe UC14-16

Entyvio (vedolizumab)

Vs

Humira®‡ (adalimumab)

‡Humira® (AbbVie Inc., North Chicago, IL). For information related to Humira, please see AbbVie.com.

See the study results

Reaching new milestones

Over 215,000 UC and CD patients in the US since the approval of Entyvio®.
29,000 physicians.

over 29k physicians have prescribed entyvio
in the US since approval18§

89% of commercially insured patients have first-line biologic unrestricted commercial coverage.

89% of commercially insured patients
have first-line biologic unrestricted commercial coverage for Entyvio19‖

Check Coverage

§This information is derived from a Symphony database of Entyvio medical and pharmacy claims from June 2014 to preliminary April 2021.

||First-line/unrestricted coverage refers to patients with no prior biologic use. Data regarding current first-line/unrestricted commercial coverage for Entyvio are derived from Managed Markets Insights & Technology (MMIT) as of July 2021.

References:

  1. Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.
  2. Briskin M, Winsor-Hines D, Shyjan A, et al. Am J Pathol. 1997;151(1):97-110.
  3. Fedyk E, Wyant T, Yang LL, et al. Inflamm Bowel Dis. 2012;18(11):2107-2119.
  4. Soler D, Chapman T, Yang LL, et al. J Pharmacol Exp Ther. 2009;330(3):864-875.
  5. Wyant T, Fedyk E, Abhyankar B. J Crohns Colitis. 2016;10(12):1437-1444.
  6. Wyant T, Leach T, Sankoh S, et al. Gut. 2015;64(1):77-83.
  7. Milch C, Wyant T, Xu J, et al. J Neuroimmunol. 2013;264:123-126.
  8. Data on file. Entyvio is the most prescribed biologic in IBD new patient starts - Supporting Data & Methodology Overview, August 2021. Takeda Pharmaceuticals USA, Inc.
  9. Data on file. MLN0002, Final CSR C13006, September 2012. Takeda Pharmaceuticals USA, Inc.
  10. Data on file. MLN0002, Final CSR C13007, October 2012. Takeda Pharmaceuticals USA, Inc.
  11. Loftus EV, Feagan BG, Panaccione R, et al; for the GEMINI LTS study team. Aliment Pharmacol Ther. 2020;00:1-13.
  12. Data on file. MLN0002, Final CSR C13008, July 2018. Takeda Pharmaceuticals USA, Inc.
  13. Data on file. Internal communication, October 2020. Takeda Pharmaceuticals USA, Inc.
  14. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. N Engl J Med. 2019;381(13):1215-1226.
  15. Data on file. DDW Abstract 416a, May 2019. Takeda Pharmaceuticals USA, Inc.
  16. Data on file. DDW Oral Presentation 416a, May 2019. Takeda Pharmaceuticals USA, Inc.
  17. Data on file. Entyvio Patient Counts - Supporting Data & Methodology Overview, June 2021. Takeda Pharmaceuticals USA, Inc.
  18. Data on file. Entyvio Prescriber Counts - Supporting Data & Methodology Overview, June 2021. Takeda Pharmaceuticals USA, Inc.
  19. Data on file. Entyvio Access Report, September 2021. Takeda Pharmaceuticals USA, Inc.